



Suggested Readings

Differential Diagnosis

- Solomon AJ, Arrambide G, Brownlee WJ, et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. *Lancet Neurol.* 2023;22(8):750-768. doi:10.1016/s1474-4422(23)00148-5
- Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. *Brain.* 2019;142(7):1858-1875. doi:10.1093/brain/awz144
- Sati P, Oh J, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. *Nat Rev Neurol.* 2016;12(12):714-722. doi:10.1038/nrneurol.2016.166
- Meaton I, Altokhis A, Allen CM, et al. Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. *Mult Scler.* 2022;28(14):2212-2220. doi:10.1177/13524585221118677

Treatment and Management

- Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. *Neurodegener Dis Manag.* 2023;13(1):47-70. doi:10.2217/nmt-2021-0058
- Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. *Mult Scler.* 2016;23(9):1233-1240. doi:10.1177/1352458516675039
- Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. *JAMA Neurol.* 2019;76(5):536. doi:10.1001/jamaneurol.2018.4905
- He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol.* 2020;19(4):307-316. doi:10.1016/s1474-4422(20)30067-3

Shared Decision-Making and Collaborative Care

- Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. *Mult Scler.* 2017 Feb;23(2):185-190. doi: 10.1177/1352458516671204. Epub 2016 Sep 28. PMID: 27663871.

- Ben-Zacharia A, Adamson M, Boyd A, et al. Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis. *Int Journal MS Care*. 2018;20(6):287-297. doi:10.7224/1537-2073.2017-070.
- Col N, Alvarez E, Springmann V, et al. Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. *MDM Policy Pract*. 2019 Oct 16;4(2):2381468319879134. doi: 10.1177/2381468319879134.
- Lugesesi A, di Iorio M, Travaglini D, Pietrolongo E, Pucci E, Onofri M. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. *Neuropsychiatr Dis Treat*. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24. PMID: 23836975; PMCID: PMC3699254.